

Helena A Yu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2575610/publications.pdf>

Version: 2024-02-01

66
papers

8,292
citations

87888

38
h-index

102487

66
g-index

68
all docs

68
docs citations

68
times ranked

9262
citing authors

#	ARTICLE	IF	CITATIONS
1	Precision medicine in non-small cell lung cancer: Current applications and future directions. <i>Seminars in Cancer Biology</i> , 2022, 84, 184-198.	9.6	106
2	Phase 1 Clinical Trial of Trametinib and Ponatinib in Patients With NSCLC Harboring KRAS Mutations. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100256.	1.1	4
3	Small-molecule targeted therapies induce dependence on DNA double-strand break repair in residual tumor cells. <i>Science Translational Medicine</i> , 2022, 14, eabc7480.	12.4	14
4	Immune biomarkers and response to checkpoint inhibition of BRAFV600 and BRAF non-V600 altered lung cancers. <i>British Journal of Cancer</i> , 2022, 126, 889-898.	6.4	8
5	Randomized Phase II Trial of Proton Craniospinal Irradiation Versus Photon Involved-Field Radiotherapy for Patients With Solid Tumor Leptomeningeal Metastasis. <i>Journal of Clinical Oncology</i> , 2022, 40, 3858-3867.	1.6	47
6	Clinical trial of proton craniospinal irradiation for leptomeningeal metastases. <i>Neuro-Oncology</i> , 2021, 23, 134-143.	1.2	56
7	Allele-Specific Role of ERBB2 in the Oncogenic Function of EGFR L861Q in EGFR-Mutant Lung Cancers. <i>Journal of Thoracic Oncology</i> , 2021, 16, 113-126.	1.1	13
8	Erlotinib and Trametinib in Patients With EGFR-Mutant Lung Adenocarcinoma and Acquired Resistance to a Prior Tyrosine Kinase Inhibitor. <i>JCO Precision Oncology</i> , 2021, 5, 55-64.	3.0	10
9	Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C-Mutant Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 2209-2215.	7.0	65
10	Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with EGFR Exon 20 Insertions. <i>Clinical Cancer Research</i> , 2021, 27, 2920-2927.	7.0	42
11	Pilot Study of Dacomitinib for Patients With Metastatic EGFR-Mutant Lung Cancers With Disease Progression After Initial Treatment With Osimertinib. <i>JCO Precision Oncology</i> , 2021, 5, 695-700.	3.0	9
12	Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer. <i>Nature Communications</i> , 2021, 12, 3697.	12.8	14
13	Multiomic Analysis of Lung Tumors Defines Pathways Activated in Neuroendocrine Transformation. <i>Cancer Discovery</i> , 2021, 11, 3028-3047.	9.4	66
14	Clinical Experience of Cerebrospinal Fluid-Based Liquid Biopsy Demonstrates Superiority of Cell-Free DNA over Cell Pellet Genomic DNA for Molecular Profiling. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 742-752.	2.8	17
15	Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS. <i>Nature Communications</i> , 2021, 12, 3770.	12.8	68
16	Targeting Aurora B kinase prevents and overcomes resistance to EGFR inhibitors in lung cancer by enhancing BIM- and PUMA-mediated apoptosis. <i>Cancer Cell</i> , 2021, 39, 1245-1261.e6.	16.8	58
17	Comprehensive molecular characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiation. <i>Journal of Hematology and Oncology</i> , 2021, 14, 170.	17.0	26
18	Management of brain metastases in lung cancer: evolving roles for radiation and systemic treatment in the era of targeted and immune therapies. <i>Neuro-Oncology Advances</i> , 2021, 3, v52-v62.	0.7	4

#	ARTICLE	IF	CITATIONS
19	Quantitative cerebrospinal fluid circulating tumor cells are a potential biomarker of response for proton craniospinal irradiation for leptomeningeal metastasis. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab181.	0.7	8
20	The Evolving Landscape of Resistance to Osimertinib. <i>Journal of Thoracic Oncology</i> , 2020, 15, 18-21.	1.1	37
21	Combination of Osimertinib and Bevacizumab as First-line Treatment for Patients With Metastatic EGFR-Mutant Lung Cancers—Reply. <i>JAMA Oncology</i> , 2020, 6, 1983.	7.1	3
22	Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients With Metastatic EGFR-Mutant Lung Cancers. <i>JAMA Oncology</i> , 2020, 6, 1048.	7.1	96
23	Lineage plasticity in cancer: a shared pathway of therapeutic resistance. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 360-371.	27.6	263
24	Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study. <i>Lancet Oncology</i> , 2020, 21, 373-386.	10.7	300
25	Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 2654-2663.	7.0	230
26	HER2-Mediated Internalization of Cytotoxic Agents in ERBB2-Amplified or Mutant Lung Cancers. <i>Cancer Discovery</i> , 2020, 10, 674-687.	9.4	149
27	Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers. <i>Clinical Cancer Research</i> , 2019, 25, 1063-1069.	7.0	257
28	Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1784-1793.	1.1	232
29	Lessons learned from routine, targeted assessment of liquid biopsies for EGFR T790M resistance mutation in patients with EGFR mutant lung cancers. <i>Acta Oncologica</i> , 2019, 58, 1634-1639.	1.8	10
30	A Novel Acquired Exon 20 EGFR M766Q Mutation in Lung Adenocarcinoma Mediates Osimertinib Resistance but is Sensitive to Neratinib and Poziotinib. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1982-1988.	1.1	27
31	Frequency and outcomes of brain metastases in patients with HER2-mutant lung cancers. <i>Cancer</i> , 2019, 125, 4380-4387.	4.1	51
32	Modern Management of Central Nervous System Metastases in the Era of Targeted Therapy and Immune Oncology. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, e59-e69.	3.8	8
33	Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers. <i>Journal of Thoracic Oncology</i> , 2019, 14, 802-815.	1.1	71
34	Exceptional responders with invasive mucinous adenocarcinomas: a phase 2 trial of bortezomib in patients with KRAS G12D-mutant lung cancers. <i>Journal of Physical Education and Sports Management</i> , 2019, 5, a003665.	1.2	23
35	EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes. <i>Journal of Clinical Oncology</i> , 2019, 37, 278-285.	1.6	286
36	Radiographic appearance of leptomeningeal disease in patients with EGFR-mutated non-small-cell lung carcinoma treated with tyrosine kinase inhibitors: a case series. <i>CNS Oncology</i> , 2019, 8, CNS42.	3.0	3

#	ARTICLE	IF	CITATIONS
37	A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers. <i>Journal of the National Cancer Institute</i> , 2019, 111, 575-583.	6.3	96
38	Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance. <i>Clinical Cancer Research</i> , 2018, 24, 3108-3118.	7.0	200
39	Effects of Co-occurring Genomic Alterations on Outcomes in Patients with <i>KRAS</i> -Mutant Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 334-340.	7.0	323
40	Twice weekly pulse and daily continuous-dose erlotinib as initial treatment for patients with epidermal growth factor receptor-mutant lung cancers and brain metastases. <i>Cancer</i> , 2018, 124, 105-109.	4.1	25
41	Acquired <i>ALK</i> and <i>RET</i> Gene Fusions as Mechanisms of Resistance to Osimertinib in <i>EGFR</i> -Mutant Lung Cancers. <i>JCO Precision Oncology</i> , 2018, 2, 1-12.	3.0	60
42	Sequencing Therapy for Genetically Defined Subgroups of Non-Small Cell Lung Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 726-739.	3.8	13
43	ERBBal Remedies: Combination Therapy for EGFR-mutant Lung Cancers. <i>Clinical Cancer Research</i> , 2018, 24, 5499-5501.	7.0	0
44	<i>YES1</i> amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E6030-E6038.	7.1	44
45	Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies. <i>Cancer Discovery</i> , 2017, 7, 596-609.	9.4	490
46	Patterns of initial and intracranial failure in metastatic EGFR-mutant non-small cell lung cancer treated with erlotinib. <i>Lung Cancer</i> , 2017, 108, 109-114.	2.0	36
47	Successful Use of Afatinib After Erlotinib-induced Pneumonitis in a Patient With Epidermal Growth Factor Receptor-mutant Lung Cancer. <i>Clinical Lung Cancer</i> , 2017, 18, e81-e83.	2.6	1
48	A Phase 1/2 Trial of Ruxolitinib and Erlotinib in Patients with EGFR -Mutant Lung Adenocarcinomas with Acquired Resistance to Erlotinib. <i>Journal of Thoracic Oncology</i> , 2017, 12, 102-109.	1.1	40
49	Identification and Functional Characterization of <i>EGFR</i> V769M, a Novel Germline Variant Associated With Multiple Lung Adenocarcinomas. <i>JCO Precision Oncology</i> , 2017, 1, 1-10.	3.0	9
50	Clinical Application of Picodroplet Digital PCR Technology for Rapid Detection of EGFR T790M in Next-Generation Sequencing Libraries and DNA from Limited Tumor Samples. <i>Journal of Molecular Diagnostics</i> , 2016, 18, 903-911.	2.8	20
51	Detection of T790M, the Acquired Resistance <i>EGFR</i> Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses. <i>Clinical Cancer Research</i> , 2016, 22, 1103-1110.	7.0	326
52	Serum Biomarkers Associated with Clinical Outcomes Fail to Predict Brain Metastases in Patients with Stage IV Non-Small Cell Lung Cancers. <i>PLoS ONE</i> , 2016, 11, e0146063.	2.5	17
53	Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib. <i>Cancer</i> , 2015, 121, 3212-3220.	4.1	160
54	EGFR: The Paradigm of an Oncogene-Driven Lung Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 2221-2226.	7.0	72

#	ARTICLE	IF	CITATIONS
55	Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring <i>MET</i> Mutations Causing Exon 14 Skipping. <i>Cancer Discovery</i> , 2015, 5, 842-849.	9.4	514
56	Differences in the survival of patients with recurrent versus de novo metastatic <i>KRAS</i> mutant and <i>EGFR</i> mutant lung adenocarcinomas. <i>Cancer</i> , 2015, 121, 2078-2082.	4.1	15
57	Prognostic Impact of <i>KRAS</i> Mutation Subtypes in 677 Patients with Metastatic Lung Adenocarcinomas. <i>Journal of Thoracic Oncology</i> , 2015, 10, 431-437.	1.1	98
58	Acquired Resistance of <i>EGFR</i> Mutant Lung Cancer to a T790M-Specific <i>EGFR</i> Inhibitor. <i>JAMA Oncology</i> , 2015, 1, 982.	7.1	214
59	Are there imaging characteristics associated with lung adenocarcinomas harboring <i>ALK</i> rearrangements?. <i>Lung Cancer</i> , 2014, 86, 190-194.	2.0	57
60	Therapeutic Strategies Utilized in the Setting of Acquired Resistance to <i>EGFR</i> Tyrosine Kinase Inhibitors. <i>Clinical Cancer Research</i> , 2014, 20, 5898-5907.	7.0	72
61	Erlotinib Versus Radiation Therapy for Brain Metastases in Patients With <i>EGFR</i> -Mutant Lung Adenocarcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 322-329.	0.8	91
62	Germline <i>EGFR</i> T790M Mutation Found in Multiple Members of a Familial Cohort. <i>Journal of Thoracic Oncology</i> , 2014, 9, 554-558.	1.1	63
63	Analysis of Tumor Specimens at the Time of Acquired Resistance to <i>EGFR</i> -TKI Therapy in 155 Patients with <i>EGFR</i> -Mutant Lung Cancers. <i>Clinical Cancer Research</i> , 2013, 19, 2240-2247.	7.0	2,097
64	Afatinib—new therapy option for <i>EGFR</i> -mutant lung cancer. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 551-552.	27.6	72
65	Local Therapy with Continued <i>EGFR</i> Tyrosine Kinase Inhibitor Therapy as a Treatment Strategy in <i>EGFR</i> -Mutant Advanced Lung Cancers That Have Developed Acquired Resistance to <i>EGFR</i> Tyrosine Kinase Inhibitors. <i>Journal of Thoracic Oncology</i> , 2013, 8, 346-351.	1.1	313
66	Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancers. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 161-169.	4.9	64